Chlorthalidone Shortage: What Providers and Prescribers Need to Know in 2026

Chlorthalidone occupies a central position in hypertension management. Endorsed as a first-line agent by the 2017 ACC/AHA guidelines and supported by the ALLHAT trial — the largest randomized antihypertensive trial ever conducted — chlorthalidone is increasingly the preferred thiazide-type diuretic over hydrochlorothiazide. Yet patients are calling practices with a familiar complaint: their pharmacy is out of stock.

This clinical overview addresses the current availability landscape, evidence-based substitution options, dosing considerations, and practical tools your care team can use to minimize disruptions to your patients' antihypertensive regimens.

Current Availability Status

As of early 2026, generic chlorthalidone is not on the FDA's Drug Shortage Database. The ASHP Drug Shortage Resource Center also does not list it as an active shortage. Multiple generic manufacturers produce 12.5 mg, 25 mg, and 50 mg tablets, and wholesale availability is generally adequate.

The problem is at the retail pharmacy level. Just-in-time inventory systems, concentrated manufacturing among a small number of generics producers, and a secular increase in chlorthalidone prescribing (driven by guideline updates) collectively produce localized stockouts. Independent pharmacies sourcing from different distributors may have stock when chain pharmacies do not.

Note: Canadian provincial shortage lists included chlorthalidone products (Jamp brand, 12.5 mg and 25 mg) as recently as late 2025. While this doesn't directly indicate US availability, North American supply chain tightness is worth monitoring.

Therapeutic Substitution Options and Dose Equivalencies

When chlorthalidone is unavailable, the following substitutions are supported by clinical evidence. Always individualize based on renal function, electrolyte status, comorbidities, and concomitant medications.

Hydrochlorothiazide (HCTZ)

HCTZ is the most widely accepted substitution. A commonly cited equivalency is chlorthalidone 12.5 mg ≈ HCTZ 25 mg, though this is not precisely established pharmacokinetically. Chlorthalidone's superior half-life (40–60 hours vs. 8–15 hours for HCTZ) means the substitution may result in modestly less 24-hour BP coverage, particularly in early morning hours. Dosing once daily in the morning is appropriate.

Typical substitution: Chlorthalidone 12.5 mg → HCTZ 12.5–25 mg daily

Typical substitution: Chlorthalidone 25 mg → HCTZ 25–50 mg daily

Monitor: electrolytes (K+, Na+), BUN/Cr 2–4 weeks after switching

Indapamide

Indapamide is a thiazide-like diuretic with additional direct vasodilatory properties. It maintains efficacy at GFR < 30 mL/min/1.73 m², making it particularly useful in patients with CKD Stage 3b–4 who need a thiazide-type agent. Typical dose: 1.25–2.5 mg once daily.

Metolazone

Metolazone is another thiazide-like option that retains diuretic efficacy at low GFRs. It is substantially more potent than chlorthalidone and more commonly used for refractory fluid overload than routine hypertension. Use with caution given risk of profound diuresis and electrolyte depletion — not a routine first substitution for hypertension.

Considerations for Patients on Chlorthalidone for Non-Hypertension Indications

Chlorthalidone is also used off-label for calcium nephrolithiasis and diabetes insipidus. For patients prescribed it for nephrolithiasis, HCTZ is a clinically reasonable and well-evidenced substitute — both reduce urinary calcium excretion and stone recurrence risk. For diabetes insipidus (nephrogenic), HCTZ or chlorpropamide may be alternatives depending on the clinical picture.

Key Drug Interaction Alerts When Switching

When initiating or switching any thiazide-type diuretic, review for:

Lithium: All thiazide-type diuretics reduce renal lithium clearance and increase toxicity risk. Monitor lithium levels closely when initiating or adjusting diuretic therapy.

Digoxin: Hypokalemia from any thiazide-type agent potentiates digoxin toxicity. Check K+ before and after transition.

NSAIDs: Reduce diuretic and antihypertensive efficacy. Counsel patients to minimize OTC NSAID use.

ACE inhibitors/ARBs + diuretic: Combination may cause first-dose hypotension, particularly if diuretic dose is increased at transition.

Monitoring After Substitution

After transitioning from chlorthalidone to any alternative, schedule follow-up labs (BMP or CMP) and a blood pressure check within 2–4 weeks. Particular attention to:

Serum potassium (hypokalemia risk with all thiazide-type agents)

Serum sodium (hyponatremia, particularly in elderly patients)

Serum creatinine and BUN (diuretic-induced prerenal azotemia)

Blood pressure (goal attainment)

Fasting glucose (thiazide-type agents can impair glucose tolerance)

Tools for Helping Your Patients Find Chlorthalidone

Rather than simply substituting when chlorthalidone is hard to find, consider directing patients to medfinder for providers. medfinder calls pharmacies near your patient to identify which ones have the medication in stock, and texts the patient results — helping avoid unnecessary switches while empowering patients to take action.

For a step-by-step protocol your front desk or care coordinator can share with patients, see our provider guide to helping patients find Chlorthalidone in stock.